Biotech firm HighTide raises $107m in Series C, C+ rounds from China investors

Biotech firm HighTide raises $107m in Series C, C+ rounds from China investors

Photo by RephiLe water on Unsplash

05 January, 2023

biotech digestive diseases HighTide Therapeutics metabolic disorders

Printed by Unregistered user on Fri, 15 Aug 2025 16:12:23 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

China's Tsingke Biotechnology secures $57m in Series B round

Venture Capital

Chinese biotech firm Trinomab closes $104m pre-IPO round to advance product pipeline

Read more from Greater China

Bridgewater sold all its US-listed China stocks, worth $1.5b, in Q2 2025

China’s Ant Group says Bright Smart acquisition on track following reports of delay